secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2023-04-26T23:59:59+00:00
Accession:  0001437749-23-011154
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Therapeutics dissident slate wins board seats; three new directors elected
--------------------------------------------------------------------------------

- Mangless-nominated directors Bode, Calder, Watton elected; company nominees Pascoe, Posner, Tierney received 3.3M, 2.7M, and 2.5M for votes vs 14.2M, 14.8M, and 15.0M withheld.
- Ratification of Ernst & Young as auditor approved with 16.3M for vs 0.3M against and 0.9M abstentions.
- Mangless Proposal to repeal bylaw changes adopted after Jan 1, 2023 passed (14.5M for, 2.9M against); no such changes existed, so it had no effect.
- Turnout: 50.73% of outstanding shares (17.5M of 34.5M) represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923011154/0001437749-23-011154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923011154/zvra20230426_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-011154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer